News
CAR T Vision Coalition Launches With Ambitious Goal
In the United States, despite the availability of CAR T-cell therapy to treat certain types of aggressive and advanced blood cancers, only about 2 out of 10 eligible patients are able to access CAR T therapy. The CAR T Vision Steering Committee was established with a goal of doubling the proportion of eligible patients treated with CAR T therapy by 2030.
The steering committee is comprised of clinical, patient support, provider, and health system experts from North America and Europe, who are working collectively to increase awareness, expand resources and capacity to deliver CAR T therapy, and manage costs of these treatments. AACI Cellular Therapy Initiative Steering Committee members Miguel-Angel Perales, MD, of Memorial Sloan Kettering Cancer Center, and Joseph McGuirk, DO, FACP, of The University of Kansas Cancer Center, are both participating in the initiative, which is endorsed by AACI.